PROM1 and cancer: Given that both CSCs and CD133pos cell fractions have been shown to exhibit chemo- and radio-resistance [83, 117, 126–129], the ability to predict how patients will respond to therapy could fulfil a significant unmet clinical need in many cancers where CD133 is overexpressed.